A clinical study of ALK's tablet vaccine against house dust mite allergy showed
an effect that was highly statistically significant and met its primary
endpoint. The study showed a 50% reduction in the use of asthma medicine.
Moreover, the study demonstrated that the tablet vaccine is well tolerated and
has a good safety profile. 

ALK today presents the headline results from a Phase II/III clinical study
(MT-02) of the company's tablet-based vaccine against house dust mite allergy.
The primary objective was to study whether patients suffering from allergic
asthma caused by house dust mite allergy can reduce their use of conventional
asthma medicine in the form of inhaled steroids when treated with the tablet
vaccine. Patients who received the highest dose of the tablet vaccine achieved
a 50% reduction (median value) in their use of inhaled steroids compared to the
amount used before treatment began (baseline). The effect was highly
statistically significant compared to placebo (p=0.0036). The study also showed
that the tablet vaccine is well tolerated and has a good safety profile. 

The study included 604 adolescent and adult patients aged from 14 years and
older who were divided into four cohorts. The patients in the first three
cohorts received active treatment by various doses of the house dust mite
tablet, whereas patients in the fourth cohort all received placebo. The study
was conducted over 18 months with a minimum treatment period of 12 months at 80
clinical centers in eight European countries. ALK expects to present additional
analyses and results from the study at upcoming scientific events. 

ALK considers the results an important milestone in its development program,
which will continue with further clinical studies with a view to obtaining a
future European approval of the product. On the North American markets, ALK has
licensed the product rights to its US partner, Schering-Plough. 

In 2007, ALK launched the world's first registered tablet-based allergy
vaccine, GRAZAX®, against grass pollen allergy. The tablet against house dust
mite allergy is the next tablet vaccine in ALK's R&D program. After grass,
house dust mite allergy is the most common type of allergy worldwide. 



About ALK
ALK is a global pharmaceutical company focusing on allergy treatment,
prevention and diagnosis. Our mission is to improve quality of life for
allergic people by developing pharmaceutical products that target the actual
cause of allergy. ALK is the world leader in allergy vaccination
(immunotherapy) - a unique treatment that induces a protective immune response
which reduces and potentially halts the allergic reaction. Allergy vaccination
is traditionally administered as subcutaneous injections or sublingual
droplets. Our aim is to extend the use of allergy vaccination by introducing
convenient, tablet-based vaccines, thereby offering many more patients a causal
allergy treatment. Following this strategy, the world's first tablet-based
vaccine against grass pollen allergy, GRAZAX®, was launched in Europe in 2006,
and ALK has entered into partnerships regarding the tablet programme with the
Menarini Group for central and Eastern Europe and with Schering-Plough for
North America. ALK has more than 1,400 employees with subsidiaries, production
facilities and distributors worldwide. The company is headquartered in
Hørsholm, Denmark and listed on the NASDAQ OMX Nordic Exchange Copenhagen.
'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'.
Further information is available at www.alk-abello.com and www.GRAZAX.com. 


For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551